Rare presentation of Fabry disease as 'burnt-out' hypertrophic cardiomyopathy

BMJ Case Rep. 2021 Sep 3;14(9):e243604. doi: 10.1136/bcr-2021-243604.

Abstract

We herein report the case of a 53-year-old man who was historically diagnosed with hypertrophic cardiomyopathy (HCM) and was lost to follow-up, before presenting with end-stage heart failure. This was initially suspected as dilated cardiomyopathy and then 'burnt-out phase' of HCM but subsequently the underlying diagnosis was Fabry disease. Fabry disease is an uncommon lysosomal-storage disease due to reduced or absent activity of the alpha-galactosidase A enzyme. Cardiac involvement most frequently comprises left ventricular hypertrophy. Early treatment of the underlying condition with enzyme replacement therapy may prevent the progression to end-stage heart failure. Fabry disease should be considered in all patients presenting with a clinical phenotype of HCM and a historical diagnosis should be re-evaluated in light of new diagnostic tools. Untreated Fabry can progress to a 'burnt out' phase, whereby initial hypertrophy undergoes eccentric remodelling to a dilated, severely impaired left ventricle.

Keywords: cardiovascular medicine; cardiovascular system; heart failure.

Publication types

  • Case Reports

MeSH terms

  • Cardiomyopathy, Hypertrophic* / diagnosis
  • Enzyme Replacement Therapy
  • Fabry Disease* / complications
  • Fabry Disease* / diagnosis
  • Fabry Disease* / drug therapy
  • Humans
  • Hypertrophy, Left Ventricular / etiology
  • Male
  • Middle Aged
  • alpha-Galactosidase / therapeutic use

Substances

  • alpha-Galactosidase